• Explore /
  • Poster
  • / Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.

Abstract Video & Slides Poster

Authors

null

Haeseong Park

Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

Haeseong Park , Michael Iglesia , Katrina Sophia Pedersen , Patrick Grierson , Zishuo Ian Hu , Rama Suresh , Benjamin R. Tan Jr., Nikolaos Trikalinos , Olivia Aranha , Katherine Navo , David G. DeNardo , Matthew A. Ciorba , Katlyn Kraft , Feng Gao , Elizabeth Martinez , Reinhard von Roemeling , Felix Geissler , Kian-Huat Lim

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT05187182

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4168)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4168

Abstract #

TPS4168

Poster Bd #

149b

Abstract Disclosures

Similar Posters

First Author: Igor Tsaur

First Author: Mark Chang

First Author: Kamaneh Montazeri

First Author: Martin Gutierrez